Stage migration with the new American Joint Committee on Cancer (AJCC) staging system (8th edition) for differentiated thyroid cancer
- PMID: 30415873
- PMCID: PMC6309303
- DOI: 10.1016/j.surg.2018.04.078
Stage migration with the new American Joint Committee on Cancer (AJCC) staging system (8th edition) for differentiated thyroid cancer
Abstract
Background: Tumor, node, and metastasis staging in thyroid carcinoma is important for assessing prognosis. However, patients with stage III or IV disease have an overall survival rate of 90%. The change to 55 years of age as the cutoff will create stage migration and many patients will be downstaged.
Methods: We reviewed our database of 3,650 patients to analyze the impact of the new American Joint Committee on Cancer staging system. There were 994 men (27%) and 2,656 women (73%). The median age was 46 years. Patients were staged using both 7th and 8th editions, with a cutoff of 55 years of age and new definitions of T3 and T4, and nodal staging.
Results: Of 3,650 patients, 1,057 (29%) were downstaged. There were 104 (10%) who went from stage IV to I, 109 (10%) who went from stage IV to stage II, and 68 (6%) who went to stage III. There were 218 (21%) who went from stage III to I, 347 (33%) who went from stage III to stage II, and 211 (20%) who went from stage II to I. The overall disease-specific and relapse-free survival was analyzed and showed better stratification with the new staging system.
Conclusion: The new staging system reflects more appropriately the biology of thyroid cancer and will have significant impact on the management of thyroid cancer.
Copyright © 2018 Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflict of Interest Statement
None declared.
Figures
Comment in
-
Discussion.Surgery. 2019 Jan;165(1):10-11. doi: 10.1016/j.surg.2018.04.083. Surgery. 2019. PMID: 30526990 No abstract available.
References
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. - PubMed
-
- Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, and Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993;114(6):1057–1058. - PubMed
-
- Cady B. Hayes Martin Lecture. Our AMES is true: how an old concept still hits the mark: or, risk group assignment points the arrow to rational therapy selection in differentiated thyroid cancer. Am J Surg. 1997;174(5):462–468. - PubMed
-
- Byar DP, Green SB, Dor P, Williams ED, Colon J, van Gilse HA, et al. A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. thyroid cancer cooperative group. Eur J Cancer. 1979;15(8):1033–1041. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
